BioNeMo enables life sciences to harness vast scientific data, accelerating AI-driven drug discovery while reducing $300 billion in annual R&D costs.
NVIDIA has announced a major expansion of its BioNeMo™ platform, an open development environment designed to accelerate AI-driven biology and drug discovery. The platform enables lab-in-the-loop workflows, turning vast amounts of scientific data into actionable intelligence to optimise experiments, train and deploy models, and reduce the $300 billion annual R&D costs in the life sciences sector.
The expanded BioNeMo now includes new NVIDIA Clara™ open models, such as RNAPro for RNA structure prediction and ReaSyn v2 to ensure AI-designed drugs are synthesizable. The platform also offers BioNeMo Recipes, which simplify and scale the training, customisation, and deployment of biological foundation models, as well as data processing libraries like nvMolKit, a GPU-accelerated cheminformatics tool for molecular design. These additions enable researchers to create continuous learning cycles where each experiment informs the next, increasing the probability of discovery success.
NVIDIA is collaborating with leading life sciences organisations to integrate BioNeMo with laboratory experiments and workflows, effectively closing the loop between AI and experimentation. Lilly has announced a co-innovation lab with NVIDIA to address persistent challenges in drug discovery, while Thermo Fisher is partnering with NVIDIA to make scientific instruments intelligent and laboratories more autonomous.
Kimberly Powell, Vice President of Healthcare at NVIDIA, highlighted that “biology and drug discovery are reaching their transformer moments” as BioNeMo enables researchers to harness AI at every stage, from data generation to model deployment. The platform positions life sciences companies to transform their data into a competitive engine for innovation, speeding up discovery and improving efficiency across research and development.
